subscribeSubscribe
FDA Confirms Paragraph IV Patent Litigation for Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Tablets

FDA Confirms Paragraph IV Patent Litigation for Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Tablets
FDA
15 Jun 2023
Share Share
Stribild (elvitegravir) Japan Tobacco v. Mylan Pharma

Stribild (elvitegravir) Japan Tobacco v. Mylan Pharma
PATENT LITIGATION
29 Jan 2019
Share Share
California reports show drug spending changes as 2 companies sue over disclosure

California reports show drug spending changes as 2 companies sue over disclosure
Ed Silverman STAT NEWS
03 Jan 2019
Share Share
China National Drug Administration Approves Gilead`s Genvoya

China National Drug Administration Approves Gilead`s Genvoya
PRESS RELEASE
06 Aug 2018
Share Share
Truvada® (emtricitabine & tenofovir disoproxil fumarate)elvitegravir, GS 9350 (cobicistat): ViiV Healthcare v. Gilead Sciences

Truvada® (emtricitabine & tenofovir disoproxil fumarate)elvitegravir, GS 9350 (cobicistat): ViiV Healthcare v. Gilead Sciences
PATENT LITIGATION
07 Feb 2018
Share Share
Gilead’s genvoya shows significantly higher rates of virologic suppression

Gilead’s genvoya shows significantly higher rates of virologic suppression
PHARMABIZ
15 Feb 2017
Share Share
The Glaxo-Gilead HIV Battle Could Be Epic

The Glaxo-Gilead HIV Battle Could Be Epic
SEEKING ALPHA
28 Dec 2016
Share Share
Gilead asks FDA to Expand Exclusivity for a Key HIV Drug

Gilead asks FDA to Expand Exclusivity for a Key HIV Drug
ED SILVERMAN STAT
21 Oct 2016
Share Share
Gilead Sciences (Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate) Approved In US

Gilead Sciences (Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate) Approved In US
FDA
07 Sep 2016
Share Share
Gilead gains next-gen HIV approval from FDA as it looks to beat back competition

Gilead gains next-gen HIV approval from FDA as it looks to beat back competition
Ben Adams FIERCE BIOTECH
06 Apr 2016
Share Share